Literature DB >> 15057428

[Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].

Carsten Herskind1, Katharina Fleckenstein, Jens Lohr, Chuan-Yuan Li, Frederik Wenz, Frank Lohr.   

Abstract

BACKGROUND: During the last 2 decades, cytokines such as interferons (IFN) have been used to modulate tumor response in radiotherapy. Initially, the focus was on antiviral and radiosensitizing effects of interferons but increasingly, the function of interferons and interleukins (IL) within the immune response to tumor cells is becoming important.
METHOD: The cellular immune response toward tumor cells is reviewed. The role of cytokines in antigen presentation and activation of effector cells and their interactions with radiation are described. Preclinical strategies of the antitumor action of cytokines are presented and discussed based on the induction of IFN-gamma by IL-12.
RESULTS: Recent advances in immunology have demonstrated the importance of local interactions between antigen-presenting cells (APC) and effector cells such as natural killer (NK) cells and T-lymphocytes for an effective immune reaction against tumors. Interferons stimulate such interactions, while IL-2 plays a central role in the activation of NK cells and T-lymphocytes. The interactions between APC and effector cells are suppressed by many tumors but can be stimulated by irradiation. Since systemic application of interferons is quite toxic, present strategies aim at local expression, e. g., the induction of IFN-gamma expression in Th1 cells by IL-12.
CONCLUSION: The improved understanding of immunologic mechanisms has emphasized the role of the cytokine network in the interaction between tumor cells and effector cells such as NK cells and T-lymphocytes. This opens new possibilities for the application of cytokines as biological response modifiers, which may eventually help widening the therapeutic window in radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057428     DOI: 10.1007/s00066-004-9119-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  5 in total

1.  Evaluation of cancer-preventive activity and structure-activity relationships of 3-demethylubiquinone Q2, isolated from the ascidian Aplidium glabrum, and its synthetic analogs.

Authors:  Sergey N Fedorov; Oleg S Radchenko; Larisa K Shubina; Nadezhda N Balaneva; Ann M Bode; Valentin A Stonik; Zigang Dong
Journal:  Pharm Res       Date:  2006-12-05       Impact factor: 4.200

2.  Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients.

Authors:  Anamika Bose; Tathagata Chakraborty; Krishnendu Chakraborty; Smarajit Pal; Rathindranath Baral
Journal:  Cancer Immun       Date:  2008-06-12

3.  Lung-protective effects of the metalloporphyrinic peroxynitrite decomposition catalyst WW-85 in interleukin-2 induced toxicity.

Authors:  Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Martin Westphal; Lillian D Traber; Perenlei Enkhbaatar; Kanneganti G K Murthy; Yoshimitsu Nakano; Andrew L Salzman; David N Herndon; Daniel L Traber
Journal:  Biochem Biophys Res Commun       Date:  2008-10-23       Impact factor: 3.575

Review 4.  Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection.

Authors:  Carsten Herskind; Frederik Wenz; Frank A Giordano
Journal:  Front Oncol       Date:  2017-07-24       Impact factor: 6.244

5.  Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma.

Authors:  Ales Sedlar; Simona Kranjc; Tanja Dolinsek; Maja Cemazar; Andrej Coer; Gregor Sersa
Journal:  BMC Cancer       Date:  2013-01-29       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.